Wai Leong Tam

Dr. Wai Leong Tam

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2006 in Cell
Verified
Journal Article
Closed access
KMKevin C. Miranda
Kevin C. Miranda
THTien Huynh
Tien Huynh
YTYvonne Tay
Yvonne Tay
YAYen-Sin Ang
Yen-Sin Ang
WTWai Leong Tam
Wai Leong Tam
Isidore RigoutsosIsidore Rigoutsos
Isidore Rigoutsos

7 November 2013 in Nature Medicine
Verified
Journal Article
Open access
PDF file
WTWai Leong Tam
Wai Leong Tam
RWRobert A Weinberg
Robert A Weinberg
Epithelial-mesenchymal transitions (EMTs) are a key requirement for cancer cells to metastasize and colonize in a new environment. Epithelial-mesenchymal plasticity is mediated by master transcription factors and is also subject to complex epigenetic regulation. This Review outlines our current understanding of the interactions between EMT-inducing transcription factors and epigenetic modulators during cancer progression and the therapeutic implications of exploiting this intricate regulatory process. During the course of malignant cancer progression, neoplastic cells undergo dynamic and reversible transitions between multiple phenotypic states, the extremes of which are defined by the expression of epithelial and mesenchymal phenotypes. This plasticity is enabled by underlying shifts in epigenetic regulation. A small cohort of pleiotropically acting transcription factors is widely recognized to effect these shifts by controlling the expression of a constituency of key target genes. These master regulators depend on complex epigenetic regulatory mechanisms, notably the induction of changes in the modifications of chromatin-associated histones, in order to achieve the widespread changes in gene expression observed during epithelial-mesenchymal transitions (EMTs). These associations indicate that an understanding of the functional interactions between such EMT-inducing transcription factors and the modulators of chromatin configuration will provide crucial insights into the fundamental mechanisms underlying cancer progression and may, in the longer term, generate new diagnostic and therapeutic modalities for treating high-grade malignancies.

1 March 2012 in Cell
Verified
Journal Article
Closed access
WGWenjun Guo
Wenjun Guo
ZKZuzana Keckesova
Zuzana Keckesova
JDJoana Liu Donaher
Joana Liu Donaher
TSTsukasa Shibue
Tsukasa Shibue
VTVerena Tischler
Verena Tischler
RWRobert A. Weinberg
Robert A. Weinberg

23 March 2014 in Nature
Verified
Journal Article
Open access
PDF file
XCXi Chen
Xi Chen
DIDimitrios Iliopoulos
Dimitrios Iliopoulos
QZQING ZHANG
QING ZHANG
QTQianzi Tang
Qianzi Tang
MGMatthew B. Greenblatt
Matthew B. Greenblatt
LGLaurie H. Glimcher
Laurie H. Glimcher
This study finds that triple-negative breast cancers (TNBC) show an increased basal level of endoplasmic reticulum stress and activation of the XBP1 branch of the unfolded protein response; furthermore, XBP1 promotes tumour formation of TNBC cell lines by interacting with and regulating HIF1α. Laurie Glimcher and colleagues report that in triple-negative breast cancers (TNBCs), the tumour cells show an increased basal level of endoplasmic reticulum stress and activation of the XBP1 branch of the unfolded protein response, a major cellular stress response pathway in the tumour microenvironment. TNBC tumours lack receptors for oestrogen, progesterone and HER2, making them recalcitrant to many drugs through an absence of targets. The authors go on to show that XBP1 promotes tumour formation in TNBC cell lines by interacting with and regulating HIF1α in the absence of hypoxia. This study highlights an important link between two major stress pathways in TNBCs and suggests possible therapeutic interventions for this aggressive form of breast cancer. Cancer cells induce a set of adaptive response pathways to survive in the face of stressors due to inadequate vascularization1. One such adaptive pathway is the unfolded protein (UPR) or endoplasmic reticulum (ER) stress response mediated in part by the ER-localized transmembrane sensor IRE1 (ref. 2) and its substrate XBP1 (ref. 3). Previous studies report UPR activation in various human tumours4,5,6, but the role of XBP1 in cancer progression in mammary epithelial cells is largely unknown. Triple-negative breast cancer (TNBC)—a form of breast cancer in which tumour cells do not express the genes for oestrogen receptor, progesterone receptor and HER2 (also called ERBB2 or NEU)—is a highly aggressive malignancy with limited treatment options7,8. Here we report that XBP1 is activated in TNBC and has a pivotal role in the tumorigenicity and progression of this human breast cancer subtype. In breast cancer cell line models, depletion of XBP1 inhibited tumour growth and tumour relapse and reduced the CD44highCD24low population. Hypoxia-inducing factor 1α (HIF1α) is known to be hyperactivated in TNBCs9,10. Genome-wide mapping of the XBP1 transcriptional regulatory network revealed that XBP1 drives TNBC tumorigenicity by assembling a transcriptional complex with HIF1α that regulates the expression of HIF1α targets via the recruitment of RNA polymerase II. Analysis of independent cohorts of patients with TNBC revealed a specific XBP1 gene expression signature that was highly correlated with HIF1α and hypoxia-driven signatures and that strongly associated with poor prognosis. Our findings reveal a key function for the XBP1 branch of the UPR in TNBC and indicate that targeting this pathway may offer alternative treatment strategies for this aggressive subtype of breast cancer.

2 September 2015 in Nature
Verified
Journal Article
Open access
PDF file
XYXin Ye
Xin Ye
WTWai Leong Tam
Wai Leong Tam
TSTsukasa Shibue
Tsukasa Shibue
YKYasemin Kaygusuz
Yasemin Kaygusuz
FRFerenc Reinhardt
Ferenc Reinhardt
RWRobert A. Weinberg
Robert A. Weinberg
This study finds that the epithelial-to-mesenchymal (EMT) transition program, which is common to both mammary gland reconstituting stem cells and mammary tumour-initiating cells, is differentially regulated by two distinct EMT factors, Slug and Snail; the findings illustrate that although they appear similar, normal tissue stem cells and tumour-initiating cells are controlled by distinct regulatory processes. The similarities between tumour initiating cells and normal tissue stem cells have led to the suggestion that the activation of a stem cell program in tissues might generate tumour initiating cells. Robert Weinberg and colleagues show here that the epithelial-to-mesenchymal (EMT) transition program, which is common to both mammary gland reconstituting stem cells and mammary gland tumour initiating cells, is differentially regulated by two distinct EMT factors, Slug and Snail. These findings illustrate that although they appear similar, normal tissue stem cells and tumour initiating cells are controlled by distinct regulatory processes. This distinction could be exploited in designing drugs to target tumour initiation. Tumour-initiating cells (TICs) are responsible for metastatic dissemination and clinical relapse in a variety of cancers1,2. Analogies between TICs and normal tissue stem cells have led to the proposal that activation of the normal stem-cell program within a tissue serves as the major mechanism for generating TICs3,4,5,6,7. Supporting this notion, we and others previously established that the Slug epithelial-to-mesenchymal transition-inducing transcription factor (EMT-TF), a member of the Snail family, serves as a master regulator of the gland-reconstituting activity of normal mammary stem cells, and that forced expression of Slug in collaboration with Sox9 in breast cancer cells can efficiently induce entrance into the TIC state8. However, these earlier studies focused on xenograft models with cultured cell lines and involved ectopic expression of EMT-TFs, often at non-physiological levels. Using genetically engineered knock-in reporter mouse lines, here we show that normal gland-reconstituting mammary stem cells9,10,11 residing in the basal layer of the mammary epithelium and breast TICs originating in the luminal layer exploit the paralogous EMT-TFs Slug and Snail, respectively, which induce distinct EMT programs. Broadly, our findings suggest that the seemingly similar stem-cell programs operating in TICs and normal stem cells of the corresponding normal tissue are likely to differ significantly in their details.

1 July 2005 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
JCJoon-Lin Chew
Joon-Lin Chew
YLYuinhan Hain Loh
Yuinhan Hain Loh
WZWensheng Zhang
Wensheng Zhang
XCXi Chen
Xi Chen
WTWai Leong Tam
Wai Leong Tam
HNHuck-Hui Ng
Huck-Hui Ng
Embryonic stem cells (ESCs) are pluripotent cells that can either self-renew or differentiate into many cell types. Oct4 and Sox2 are transcription factors essential to the pluripotent and self-renewing phenotypes of ESCs. Both factors are upstream in the hierarchy of the transcription regulatory network and are partners in regulating several ESC-specific genes. In ESCs, Sox2 is transcriptionally regulated by an enhancer containing a composite sox-oct element that Oct4 and Sox2 bind in a combinatorial interaction. It has previously been shown that Pou5f1, the Oct4 gene, contains a distal enhancer imparting specific expression in both ESCs and preimplantation embryos. Here, we identify a composite sox-oct element within this enhancer and show that it is involved in Pou5f1 transcriptional activity in ESCs. In vitro experiments with ESC nuclear extracts demonstrate that Oct4 and Sox2 interact specifically with this regulatory element. More importantly, by chromatin immunoprecipitation assay, we establish that both Oct4 and Sox2 bind directly to the composite sox-oct elements in both Pou5f1 and Sox2 in living mouse and human ESCs. Specific knockdown of either Oct4 or Sox2 by RNA interference leads to the reduction of both genes9 enhancer activities and endogenous expression levels in addition to ESC differentiation. Our data uncover a positive and potentially self-reinforcing regulatory loop that maintains Pou5f1 and Sox2 expression via the Oct4/Sox2 complex in pluripotent cells.